Atlas Trials

A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)

Clinical trial NCT05810961 · TERMINATED

Trial details

NCT number
NCT05810961
Sponsor
argenx
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Membranous Nephropathy
Start date
2023-02-20
Primary completion
2024-08-05
Enrollment
8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.